Welcome to our dedicated page for ERYP news (Ticker: ERYP), a resource for investors and traders seeking the latest updates and insights on ERYP stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ERYP's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ERYP's position in the market.
ERYTECH Pharma has successfully completed enrollment in the TRYbeCA-1 Phase 3 trial for eryaspase, targeting second-line metastatic pancreatic cancer. A total of 510 patients participated, surpassing the target of 482. The trial has now accrued the necessary events for an interim superiority analysis, expected in Q1 2021. If the results indicate significant survival benefits, the trial may conclude early, paving the way for regulatory filings in the U.S. and Europe later in 2021. Eryaspase holds Fast Track and Orphan Drug Designation, highlighting its potential in addressing unmet medical needs.
ERYTECH Pharma (Nasdaq & Euronext: ERYP) announced that CEO Gil Beyen will present at the JMP Securities Hematology Summit on December 15, 2020, at 1:30 PM EST. The presentation will feature a 'fireside chat' format hosted by Reni Benjamin of JMP Securities. The event will be conducted virtually, with all participants joining remotely. A webcast of the discussion will be available on ERYTECH's website. The company is focused on developing innovative therapies targeting severe cancers and orphan diseases using its proprietary ERYCAPS® technology.
The press release outlines the share capital data for ERYP as of November 30, 2020. The total number of shares composing the share capital stands at 19,564,173, with total gross voting rights at 21,099,109 and net voting rights at 21,096,609. This reflects a consistent increase from earlier months, indicating a growth trajectory for the company’s share structure. The report also highlights that these figures are calculated per regulatory standards set by the French Autorité des marchés financiers, implying compliance with financial regulations.
ERYTECH Pharma has announced the successful results from the Phase 2 trial of eryaspase for patients with acute lymphoblastic leukemia (ALL) who have hypersensitivity to PEG-asparaginase. The trial, conducted by NOPHO across 21 sites, involved 55 patients and met primary objectives around safety and asparaginase activity, showing sustained enzyme levels in 54 out of 55 participants. Eryaspase was well tolerated, with only two severe allergic reactions. The findings highlight its potential as an effective alternative treatment for ALL, addressing a significant unmet need.
ERYTECH Pharma (Nasdaq & Euronext: ERYP) has announced a webcast on December 7 at 4:00 pm CET/10:00 am ET to discuss the results of the NOPHO Phase 2 trial for eryaspase in patients with Acute Lymphoblastic Leukemia (ALL). The trial involved 55 patients and aimed to evaluate the safety of eryaspase as a treatment alternative for those with hypersensitivity to PEG-asparaginase. The findings will be presented at the 62nd ASH Annual Meeting on December 6.
ERYTECH Pharma (Nasdaq & Euronext: ERYP) announced that CEO Gil Beyen will present at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 12:00 PM EST. A live webcast of the event will be available on the company's website.
ERYTECH is a clinical-stage biopharmaceutical company focused on developing red blood cell-based therapeutics for cancer and orphan diseases. Their lead candidate, eryaspase, is in Phase 3 for second-line pancreatic cancer and Phase 2 for triple-negative breast cancer.
ERYTECH Pharma reported a significant milestone in its clinical trials, with the TRYbeCA-1 Phase 3 trial for metastatic pancreatic cancer reaching over 95% enrollment. An interim superiority analysis is expected in Q1 2021. The NOPHO-sponsored Phase 2 trial in acute lymphoblastic leukemia completed enrollment with 55 patients, and top-line data will be presented at ASH in December 2020. The company secured €10 million in state-guaranteed loans and reported cash reserves of €40.5 million as of September 30, 2020, aiding its operational runway into 2021.
ERYTECH Pharma (Nasdaq & Euronext: ERYP) announced the selection of an abstract for an oral presentation at the 62nd American Society of Hematology Annual Meeting. This includes results from the NOPHO-sponsored Phase 2 trial of eryaspase in acute lymphoblastic leukemia (ALL) patients. The trial evaluated eryaspase's safety and efficacy for patients with hypersensitivity to pegylated asparaginase. Additionally, a second abstract concerning population pharmacokinetics of eryaspase in ALL and pancreatic adenocarcinoma patients will be featured as a poster presentation. Both presentations aim to demonstrate the potential of eryaspase in treating hemato-oncological conditions.
On November 4, 2020, ERYTECH Pharma announced its share capital details. As of October 31, 2020, the company had a total of 19,081,988 shares and 20,616,679 gross voting rights, with net voting rights at 20,614,179. The report includes data from prior months, showing a gradual increase in both shares and voting rights. ERYTECH is listed on Euronext Paris and the Nasdaq Global Select Market. This update complies with regulatory requirements specified by the French Autorité des Marchés Financiers.
ERYTECH Pharma has secured €10 million in non-dilutive financing from Bpifrance and Société Générale through a State-Guaranteed Loan (PGE Loan) amid the COVID-19 pandemic. This funding is expected to extend the company's cash runway into Q3 2021, supporting its ongoing clinical programs for eryaspase, its lead product candidate targeting cancer metabolism. Each lender will provide €5 million with a government guarantee covering 90% of the loan amounts. This financial boost underpins ERYTECH's commitment to advancing its innovative therapies.
FAQ
What is the market cap of ERYP (ERYP)?
